Guardant Health was awarded nearly $293 million in damages in a false advertising trial against competitor Natera. The verdict was rendered on December 2, 2024, following allegations that Natera made false and misleading statements to promote its Signatera cancer test over Guardant's Reveal product.
This legal victory underscores Guardant Health's commitment to defending its market position and product claims against competitors. The substantial damages award is a material financial gain for the company.
The dispute centered on Natera's alleged efforts to convince customers to use its cancer test instead of Guardant's rival offering. This outcome reinforces Guardant's standing in the competitive liquid biopsy market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.